Guidance
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
All guidance on this topic (9)
- Published guidance (8)
- New guidance in the last 6 months (1)
- Updated guidance in the last 6 months (0)
NICE advice
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
- Published advice (3)
- New advice in the last 6 months (0)
- Updated advice in the last 6 months (0)
Quality standards
Set out priority areas for quality improvement in health and social care.
NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject.
Guidance by programme
-
NICE guidelines (5)
Review the evidence across broad health and social care topics.
-
Technology appraisal guidance (4)
Review clinical and cost effectiveness of new treatments.
Advice by programme
-
Evidence summaries (3)
Review the best available evidence for selected medicines.
Products being developed or updated
-
In development (2)
Guidance, quality standards and advice being developed.
NICE Pathways
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.
-
-
Coexisting severe mental illness and substance misuse: community health and social care services
-
Psychosis and schizophrenia
NICE guidelines
Review the evidence across broad health and social care topics.
-
Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings (CG120)
-
Coexisting severe mental illness and substance misuse: community health and social care services (NG58)
-
Psychosis and schizophrenia in adults: prevention and management (CG178)
-
Psychosis and schizophrenia in children and young people: recognition and management (CG155)
Quality standards
Set out priority areas for quality improvement in health and social care.
-
Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)
-
Psychosis and schizophrenia in adults (QS80)
Technology appraisal guidance
Review clinical and cost effectiveness of new treatments.
-
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
-
Guidance on the use of electroconvulsive therapy (TA59)
-
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)
-
Structural neuroimaging in first-episode psychosis (TA136)
Evidence summaries
Review the best available evidence for selected medicines.
-
Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)
-
Schizophrenia: lurasidone (ESNM48)
-
Schizophrenia: omega-3 fatty acid medicines (ESUOM19)
In development
-
Coexisting severe mental illness and substance misuse
-
Rehabilitation in adults with complex psychosis and related severe mental health conditions
New guidance and advice
Guidance and advice added since March 2018
Putting guidance into practice
Shared learning
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 3 of 10 shared learning examples for this topic:
-
Improving Physical Health for People with Serious Mental Illness (SMI)
-
Implementing 'Preventing ill health by risky behaviours: Alcohol screening and interventions (brief advice or referral)’
-
SUFARI – a substance use tool for mental health services